Department of Clinical Sciences, Neurosciences, Umeå University, Umeå, Sweden.
Department of General Pediatrics, University of Münster, Münster, Germany.
J Inherit Metab Dis. 2020 Nov;43(6):1370-1381. doi: 10.1002/jimd.12306. Epub 2020 Sep 14.
Congenital disorders of glycosylation (CDG) are a growing group of inborn metabolic disorders with multiorgan presentation. SLC39A8-CDG is a severe subtype caused by biallelic mutations in the manganese transporter SLC39A8, reducing levels of this essential cofactor for many enzymes including glycosyltransferases. The current diagnostic standard for disorders of N-glycosylation is the analysis of serum transferrin. Exome and Sanger sequencing were performed in two patients with severe neurodevelopmental phenotypes suggestive of CDG. Transferrin glycosylation was analyzed by high-performance liquid chromatography (HPLC) and isoelectric focusing in addition to comprehensive N-glycome analysis using matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry (MS). Atomic absorption spectroscopy was used to quantify whole blood manganese levels. Both patients presented with a severe, multisystem disorder, and a complex neurological phenotype. Magnetic resonance imaging (MRI) revealed a Leigh-like syndrome with bilateral T2 hyperintensities of the basal ganglia. In patient 1, exome sequencing identified the previously undescribed homozygous variant c.608T>C [p.F203S] in SLC39A8. Patient 2 was found to be homozygous for c.112G>C [p.G38R]. Both individuals showed a reduction of whole blood manganese, though transferrin glycosylation was normal. N-glycome using MALDI-TOF MS identified an increase of the asialo-agalactosylated precursor N-glycan A2G1S1 and a decrease in bisected structures. In addition, analysis of heterozygous CDG-allele carriers identified similar but less severe glycosylation changes. Despite its reliance as a clinical gold standard, analysis of transferrin glycosylation cannot be categorically used to rule out SLC39A8-CDG. These results emphasize that SLC39A8-CDG presents as a spectrum of dysregulated glycosylation, and MS is an important tool for identifying deficiencies not detected by conventional methods.
先天性糖基化障碍(CDG)是一组不断增加的遗传性代谢疾病,具有多器官表现。SLC39A8-CDG 是一种严重的亚型,由锰转运蛋白 SLC39A8 的双等位基因突变引起,降低了许多酶包括糖基转移酶的这种必需辅因子的水平。目前,N-糖基化紊乱的诊断标准是血清转铁蛋白分析。对两名具有严重神经发育表型的患者进行了外显子组和 Sanger 测序,这些表型提示 CDG。除了使用基质辅助激光解吸电离飞行时间(MALDI-TOF)质谱(MS)进行综合 N-聚糖分析外,还通过高效液相色谱(HPLC)和等电聚焦分析转铁蛋白糖基化。原子吸收光谱用于定量全血锰水平。两名患者均表现出严重的多系统疾病和复杂的神经表型。磁共振成像(MRI)显示类似于 Leigh 的综合征,基底节区双侧 T2 高信号。在患者 1 中,外显子组测序鉴定了先前未描述的 SLC39A8 同源纯合变体 c.608T>C [p.F203S]。患者 2 被发现为 c.112G>C [p.G38R]的纯合子。尽管转铁蛋白糖基化正常,但两个人的全血锰都减少了。使用 MALDI-TOF MS 的 N-聚糖分析鉴定出无唾液酸-半乳糖基化前体 N-聚糖 A2G1S1 的增加和双分叉结构的减少。此外,对杂合 CDG-等位基因携带者的分析鉴定出类似但程度较轻的糖基化变化。尽管它作为临床金标准,但转铁蛋白糖基化分析不能被明确用于排除 SLC39A8-CDG。这些结果强调 SLC39A8-CDG 表现为糖基化失调谱,MS 是识别常规方法无法检测到的缺陷的重要工具。